‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

This story was reported by Europe News. EUROPES curates Europe's most relevant coverage — read the full report at the original source.

Read full coverage at Europe News →

‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid

More from Economy & Money

Australia dock workers call for 28-hour week in AI talks

Hundreds of jobs at risk as John Lewis plans to cut some services

Victims of 23andMe data breach to get $47m payout, judge rules

Package holidays to Dubai and Egypt cheaper as European prices creep up

From mouthwash to hair dye: How weight-loss jabs are changing shopping habits

'You have to say no': Families struggling with holiday food costs